Benchmark lowered the firm’s price target on Harvard Bioscience (HBIO) to $4.50 from $5.50 and keeps a Speculative Buy rating on the shares. End-user markets in biomedical research continue to be challenging for Harvard, says the analyst, who is lowering estimates as a result.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO: